| Interaction Color Code | Clinical Bottom Line | Clinical Effects | Drug 1 effect | Drug 2 dose | Drug 2 effect | Management | |
|---|---|---|---|---|---|---|---|
| Darunavir Pravastatin 885 | Yellow: Adjust dosing | Adjust dosing to avoid increased levels of pravastatin | Increased risk of pravastatin adverse effects (e.g. myopathy, rhabdomyolysis) |
Not studied |
40 mg x 1 | Cmax increase 63%, AUC increase 81% |
Use lowest possible starting dose, monitor for toxicity and titrate. |
| Efavirenz Pravastatin 371 | Yellow: Adjust dosing | Adjust dosing to avoid reduced levels of pravastatin | Decreased pravastatin effects |
No significant change |
40 mg daily x 4 days | Pravastatin AUC decreased 44%; Cmax decreased 32%; Cmin decreased 19% |
Monitor statin efficacy. May need to increase pravastatin dose |
| Efavirenz Pravastatin 370 | Yellow: Adjust dosing | Adjust dosing to avoid reduced levels of pravastatin | Decreased lipid effects |
No significant change |
40 mg daily on days 0-3 and 15-18 | Pravastatin AUC decreased 40% |
Monitor statin efficacy. May need to increase pravastatin dose |
| Raltegravir Pravastatin 304 | Green: Administer standard doses | Administer standard doses | Raltegravir Cmax increased 31%; Cmin decreased 41% |
40 mg daily | No significant change |
||
| Raltegravir Pravastatin 303 | Green: Administer standard doses | Administer standard doses | Raltegravir AUC no significant change; Cmax increased 31%; Cmin decreased 41% |
40 mg daily | No significant change |
